sumanirole sumanirole sumanirole (pnu-95,666) is a highly selective d2 receptor full agonist, the first of its kind to be discovered. it was developed for the treatment of parkinson's disease and restless leg syndrome. while it has never been approved for medical use it is a highly valuable tool compound for basic research to identify neurobiological mechanisms that are based on a dopamine d2-linked (vs. d1-, d3-, d4-, and d5-linked) mechanism of action. sumaniroleclinical dataother namespnu-95,666atc codenoneidentifiers iupac name (r)-5,6-dihydro-5-(methylamino)-4h-imidazoquinolin-2(1h)-one cas number179386-43-7 179386-44-8 (maleate)pubchem cid9818479iuphar/bps3949chemspider7994229unii3e93iv1u45chemblchembl419792chemical and physical dataformulac11h13n3omolar mass203.245 g·mol−13d model (jsmol)interactive image smiles cn1cc2cccc3c(=o)n(c1)c23 in 2004, pfizer announced the end of their clinical development program for sumanirole, citing “recent studies that failed to sufficiently distinguish sumanirole from currently available therapies”.